SLA2: A Protein Role in Tumorigenesis and Treatment (G84174)
SLA2: A Protein Role in Tumorigenesis and Treatment
SLA2 (Src-like adapter 2) is a protein that is expressed in various tissues throughout the body. It is a member of the Src family of adapter proteins, which play a crucial role in the intracellular signaling systems of many cell types. SLA2 is Highly conserved across various species, and its only eukaryotic transcript (SLA2-ASP2) consists of 114 amino acids.
SLA2 plays an important role in cell signal transduction. The expression level of SLA2 changes in many tumors and is associated with tumor invasion and growth. Overexpression of SLA2 is associated with poor prognosis in many tumors, including breast, lung, prostate, and colon cancers.
SLA2 is also closely related to many important cellular processes, including cell proliferation, apoptosis, migration, and extracellular matrix (ECM) deposition. In neuroscience, SLA2 plays a key role in the identification and maintenance of synapses between neurons.
In addition, SLA2 interacts with many proteins, including with the neuronal surface marker CD73. CD73 is a glycoprotein that is mainly expressed on neurons and can interact with SLA2 and recognize neuronal surface markers, thereby participating in interactions between neurons.
Mutations in SLA2 lead to the development of various tumor types. SLA2 gene mutations can cause tumors, including breast cancer, lung cancer, prostate cancer, and colon cancer. These mutations can lead to changes in the function of SLA2, thereby affecting cell signaling.
The detection of SLA2 is of great significance for tumor diagnosis, treatment and prognosis judgment. By detecting the expression levels and mutations of SLA2, doctors can better understand tumor development trends and treatment response. In addition, SLA2 can also be used as a potential drug target.
The role of SLA2 in tumor treatment is receiving more and more attention. Some studies have shown that inhibiting the function of SLA2 can significantly inhibit tumor growth and metastasis. In addition, the expression level of SLA2 is closely related to the depth of tumor invasion and the response to tumor treatment.
In conclusion, SLA2 is a protein that plays an important role in tumorigenesis. By detecting the expression levels and mutations of SLA2, doctors can better understand tumor development trends and treatment response. With the deepening of SLA2 research, SLA2 may also become an important target for future tumor treatment.
Protein Name: Src Like Adaptor 2
Functions: Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins
More Common Targets
SLAIN1 | SLAIN2 | SLAM Family Member | SLAMF1 | SLAMF6 | SLAMF6P1 | SLAMF7 | SLAMF8 | SLAMF9 | SLBP | SLC corepressor complex | SLC10A1 | SLC10A2 | SLC10A3 | SLC10A4 | SLC10A5 | SLC10A6 | SLC10A7 | SLC11A1 | SLC11A2 | SLC12A1 | SLC12A2 | SLC12A2-DT | SLC12A3 | SLC12A4 | SLC12A5 | SLC12A5-AS1 | SLC12A6 | SLC12A7 | SLC12A8 | SLC12A9 | SLC13A1 | SLC13A2 | SLC13A3 | SLC13A4 | SLC13A5 | SLC14A1 | SLC14A2 | SLC15A1 | SLC15A2 | SLC15A3 | SLC15A4 | SLC15A5 | SLC16A1 | SLC16A10 | SLC16A11 | SLC16A12 | SLC16A13 | SLC16A14 | SLC16A2 | SLC16A3 | SLC16A4 | SLC16A5 | SLC16A6 | SLC16A6P1 | SLC16A7 | SLC16A8 | SLC16A9 | SLC17A1 | SLC17A2 | SLC17A3 | SLC17A4 | SLC17A5 | SLC17A6 | SLC17A7 | SLC17A8 | SLC17A9 | SLC18A1 | SLC18A2 | SLC18A3 | SLC18B1 | SLC19A1 | SLC19A2 | SLC19A3 | SLC1A1 | SLC1A2 | SLC1A3 | SLC1A4 | SLC1A5 | SLC1A6 | SLC1A7 | SLC20A1 | SLC20A1-DT | SLC20A2 | SLC22A1 | SLC22A10 | SLC22A11 | SLC22A12 | SLC22A13 | SLC22A14 | SLC22A15 | SLC22A16 | SLC22A17 | SLC22A18 | SLC22A18AS | SLC22A2 | SLC22A20P | SLC22A23 | SLC22A24 | SLC22A25